Wednesday, April 25, 2018 12:16:49 PM
Assuming the share float is 20 million by then, without FDA approval but granted accelerated status $4 or an $80 million market cap?
With FDA approval the PPs maybe 10x that number($40, market cap 800 million)?
In the event of a partnership and FDA approval the PPS could be 15x ($60, market cap 1.2 billion)?
I continue to hold my nose and dollar cost average purchases as only buyers post split will make any real money here.
The BOD and PN are certainly increasing their shares (at our expense). 20k of options puts most of the BOD in the top 10 on the institutional list of ownership. PN with 130,000 new shares now has roughly as many shares as the top four institutions and dwarfs UT.
Like I said would happen before the reverse split, the deck is stacked in PN's favor.
As long as PN has enough funds to run the company why move the trials forward? He makes 600k per year and 130,000 in options. The longer it takes to move the drug forward, the more shares he will have IF the Prexigebersen is ever finally approved. I do not see any need for urgency on management's part and the contrary may be true.
Here is an update on the institutional ownership:
https://www.nasdaq.com/symbol/bpth/institutional-holdings
Recent BPTH News
- Bio-Path Holdings Announces Publication in Biomedicines • GlobeNewswire Inc. • 09/16/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 09:10:15 PM
- Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:15:26 PM
- Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors • GlobeNewswire Inc. • 08/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 11:30:23 AM
- Bio-Path Holdings Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:41:00 PM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024 • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:14:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:10:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 10:07:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:56:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:38:40 PM
- Bio-Path Holdings Provides Clinical Update and Expansion Plans • GlobeNewswire Inc. • 07/08/2024 11:00:00 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/17/2024 12:00:36 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/17/2024 04:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 09:10:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 11:18:17 AM
- Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress • GlobeNewswire Inc. • 06/14/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/11/2024 09:30:47 PM
- Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/05/2024 09:46:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:20:35 PM
- Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM